Navigation Links
OncoGenex Pharmaceuticals to Release First Quarter Financial Results
Date:4/30/2009

BOTHELL, WA and VANCOUVER, April 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company's first quarter financial results will be released on Thursday May 7, 2009, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon. Management will discuss the company's first quarter results and provide an update on the business and product pipeline.

To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 800-967-7143 (U.S. & Canada) or 719-325-2413 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed enrollment in a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...hasbeenmetforpatientswithadvanced-stage,orrecurren...swire-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ...mpanyfocusedonendocrinetherapyandoncology,todayann...argetedcytotoxicpeptideconjugate,AEZS-108(formerly...alcancer.Inapersonalizedhealthcareapproach,thestud...
(Date:11/24/2009)...swire-FirstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ...,announcedthatithassubmittedaMAAtotheEuropeanMedic...replacementtherapyindevelopment,forthetreatmentofT...tionforvelaglucerasealfathathasbeensubmitted,withp..., Basedonaglobalsupplyshortageofthecurrentlyappr...
(Date:11/24/2009)...24/PRNewswire-FirstCall/--GenomicHealth,Inc.(Nasda...h,sExecutiveChairman,willpresentatthe21stAnnualPip...y,December1,2009at10:00a.m.ET. ,, Toaccesstheli...visittheInvestorRelationssectionofGenomicHealth,sw...connecttothewebsiteatleast15minutespriortothebegin...
(Date:11/24/2009)...am Connects Customers with Partners Validated to P...tek Products , Ottawa, ON...ding provider of products for biological sample co...ounced its new global partner program. The program... partner community and is designed to help partner...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...obix to Acquire Commercialized Thrombolytic and Re... Million, TUCSON, Ariz., May 7 ImaRx Therapeuti...has signed a letter of intent in,which Microbix Bi...ted,assets from ImaRx for $17 million in cash. Uro...ssolving agent, indicated for the treatment of,acu...
...ng Digital Mammography Revenue Growth and FDA Appr...wth in 2008; Affirms First Half 2008 Financial ...onference Call Begins Today at 10:00 a.m. ET, NAS...dustry-leading provider of Computer-Aided Detectio...cancer, today announced financial,results for the ...
...amounts are in U.S. dollars, QUEBEC CITY, May 7 /...DAQ: AEZS , TSX: AEZ), a global biopharmaceutical...day reported financial and operating results,for t...arter 2008 Highlights, - Cetrorelix: first patien...e 3 program in benign prostatic hyperplasia (BPH);...
Other Biology Technology:ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 2ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 3ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 4iCAD Reports First Quarter 2008 Financial Results 2iCAD Reports First Quarter 2008 Financial Results 3iCAD Reports First Quarter 2008 Financial Results 4iCAD Reports First Quarter 2008 Financial Results 5iCAD Reports First Quarter 2008 Financial Results 6iCAD Reports First Quarter 2008 Financial Results 7iCAD Reports First Quarter 2008 Financial Results 8iCAD Reports First Quarter 2008 Financial Results 9AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 7
(Date:11/23/2009)... N.H. University of New Hampshire microbiologist ...15 to advance understanding of the actinorhizal pl...rich nutrient-poor and contaminated soils. , Th...warded Tisa, a professor of molecular, cellular an...biotic relationship between the bacteria Frankia a...
(Date:11/23/2009)...ity of Southern California biomedical engineer and...a new tool to help clinicians distinguish cardiac ...ic problems manageable with drugs and lifestyle ch...erted into the arteries feeding the heart, offer a... these blood vessels, often revealing deposits of ...
(Date:11/23/2009)...s like frogs and toads have existed for 360 millio...t a new aquatic fungus is threatening to make many...ovember issue of Microbiology Today . , The fu...ound to be associated with waves of amphibian exti...alia in the 1990,s. Bd infects over 350 amphibian ...
Breaking Biology News(10 mins):UNH prof. receives nearly $500,000 to research environmentally significant plants 2Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2Europe and China watching Earth together 9004 1Europe and China watching Earth together 9004 2Computers aid in cracking deception in plants 9002 1Computers aid in cracking deception in plants 9002 2ATS Medical Announces Participation in the Joint Meeting of the Society for Heart Valve Disease and Heart Valve Society of America 50067 1ATS Medical Announces Participation in the Joint Meeting of the Society for Heart Valve Disease and Heart Valve Society of America 50067 2ATS Medical Announces Participation in the Joint Meeting of the Society for Heart Valve Disease and Heart Valve Society of America 50067 3ATS Medical Announces Participation in the Joint Meeting of the Society for Heart Valve Disease and Heart Valve Society of America 50067 4
...ate red wine consumption is beneficial to cardiova...lcohol?, Take heart: laboratory research, just pre...ux, France, showed that Concord grape juice stimul...shion to red wine. The French researchers also rep...nged relaxation effect that has not yet been repor...
...researcher has developed a new technique that can ... diagnose the bacteria which causes the most commo...ce, from QUT,s Faculty of Science, has developed a... pinpoint the bacteria Campylobacter jejuni. , "C...erial food-borne gastroenteritis in westernised co...
... new biometrics to be stored on ...Domestic and global security,threats, coupled with...ading governments across the world to pursue the i...vel documents (MRTDs) to their citizens.,Entrust, ...oyment and,innovation, has announced the developme...
Other Biology News:Fighting the spread of food poisoning 2Entrust Continues Leadership by Adding Support for Next-generation E-Passports 2Entrust Continues Leadership by Adding Support for Next-generation E-Passports 3
Rabbit Anti-oligophrenin-1 Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Anti-G Protein Gi-alpha-1 Monoclonal Antibody, Unconjugated, Clone R4 from CHEMICON
Goat Anti-KOR-1 Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Mouse Oligodendrocyte Differentiation Kit from R&D Systems
Biology Products: